Clinical Trial: An Interventional, Not Pharmacological Study to Evaluate Impact(R) As Support to Anti PD1 Treatment in Patients with Inoperable Locally Advanced or Metastatic Melanoma

U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06880198) titled 'An Interventional, Not Pharmacological Study to Evaluate Impact(R) As Support to Anti PD1 Treatment in Patients with Inoperable Locally Advanced or Metastatic Melanoma' on March 11.

Brief Summary: This is a monocentric, prospective study evaluating the effectiveness in reducing immune-related adverse events, and translational study conducted on 20 patients with inoperable locally advanced or metastatic melanoma.

The patients will be treated with Oral Impact(R) administered at the dose of two bricks/day for 21 days + one brick/day for 14 days, starting exactly one week before Anti PD-1 treatment (nivolumab) as per clinical practice...